



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



3-hydroxy Darifenacin

Item No. 27852

CAS Registry No.: 206048-82-0
Formal Name: (3S)-1-[2-(2,3-dihydro-3-hydroxy-5-benzofuranyl)ethyl]- α,α -diphenyl-3-pyrrolidineacetamide
Synonym: UK 148993
MF: C₂₈H₃₀N₂O₃
FW: 442.6
Purity: $\geq 95\%$
Supplied as: A solid
Storage: -20°C
Stability: ≥ 2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

3-hydroxy Darifenacin is supplied as a solid. A stock solution may be made by dissolving the 3-hydroxy darifenacin in the solvent of choice. 3-hydroxy Darifenacin is soluble in organic solvents such as methanol and DMSO, which should be purged with an inert gas.

Description

3-hydroxy Darifenacin is a metabolite of darifenacin (Item No. 14424).^{1,2} It is an antagonist of M₁₋₅ muscarinic receptors (K_s = 17.78, 79.43, 2.24, 36.31, and 6.17 nM, respectively, in CHO cells).³

References

1. Beaumont, K.C., Cussans, N.J., Nichols, D.J., *et al.* Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man. *Xenobiotica* **28(1)**, 63-75 (1998).
2. Kerbusch, T., Wählby, U., Milligan, P.A., *et al.* Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first-pass metabolism, CYP2D6 genotype and formulation-dependent bioavailability. *Br. J. Clin. Pharmacol.* **56(6)**, 639-652 (2003).
3. Mansfield, K.J., Chandran, J.J., Vaux, K.J., *et al.* Comparison of receptor binding characteristics of commonly used muscarinic antagonists in human bladder detrusor and mucosa. *J. Pharmacol. Exp. Ther.* **328(3)**, 893-899 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 04/24/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM